According to patients, efficacy, tolerability profile, and quality of life should be prioritized when choosing a CML treatment, but many face the burden of low-grade AEs that may threaten adherence, responses, and long-term outcomes.1-4
See how adherence impacts efficacy
Discover how time on the initial TKI may affect long-term outcomes
Watch videos about important topics in CML featuring experts, patients, and more
It's very difficult to take a medication every day that makes you feel unwell.
–Actual CML patient
AE, adverse event; CML, chronic myeloid leukemia; QOL, quality of life; TKI, tyrosine kinase inhibitor.
References: 1. Clements J, Ruiz C, Damon A, et al. Poster presentation at: SOHO 2023 Eleventh Annual Meeting; September 6-9, 2023; Houston, TX, and virtual. 2. Marin D, Bazeos A, Mahon F-X, et al. J Clin Oncol. 2010;28(14):2381-2388. 3. de Almeida MH, Fogliatto L, Couto D. Rev Bras Hematol Hemoter. 2014;36(1):54-59. 4. Geissler J, Sharf G, Bombaci F, et al. J Cancer Res Clin Oncol. 2017;143(7):1167-1176.